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Abstract
Expression of C1q, an early component of the classical complement pathway, has been shown to
be induced in neurons in hippocampal slices, following accumulation of exogenous Aβ42. Microglial
activation was also detected by surface marker expression and cytokine production. To determine
whether C1q induction was correlated with intraneuronal Aβ and/or microglial activation, D-(-)-2-
amino-5-phosphonovaleric acid (APV, an NMDA receptor antagonist) and glycine-arginine-glycine-
aspartic acid-serine-proline peptide (RGD, an integrin receptor antagonist), which blocks and
enhances Aβ42 uptake, respectively, were assessed for their effect on neuronal C1q synthesis and
microglial activation. APV inhibited, and RGD enhanced, microglial activation and neuronal C1q
expression. However, addition of Aβ10–20 to slice cultures significantly reduced Aβ42 uptake and
microglial activation, but did not alter the Aβ42-induced neuronal C1q expression. Furthermore,
Aβ10–20 alone triggered C1q production in neurons, demonstrating that neither neuronal Aβ42
accumulation, nor microglial activation is required for neuronal C1q upregulation. These data are
compatible with the hypothesis that multiple receptors are involved in Aβ injury and signaling in
neurons. Some lead to neuronal C1q induction, whereas other(s) lead to intraneuronal
accumulation of Aβ and/or stimulation of microglia.
Introduction
Alzheimer's disease (AD) is the most common form of
dementia in the elderly. Its main pathological features
include extracellular amyloid beta (Aβ) deposition in
plaques, neurofibrillary tangles (composed of hyperphos-
phorylated tau protein) in neurons, progressive loss of
synapses and cortical/hippocampal neurons, and upregu-
lation of inflammatory components including activated
microglia and astrocytes and complement activation [1].
Although the contribution of abnormal phosphorylation
and assembly of tau to AD dementia remains a focus of
investigation, therapies that interfere with Aβ production,
enhance its degradation, or cause its clearance from the
central nervous system (CNS) have been the center of
many studies in search of a cure for this disease.
Microglial cells, when activated, are believed to be respon-
sible for much of the Aβ clearance through receptor-medi-
ated phagocytosis [2,3]. Upon activation, microglia
acquire features more characteristic of macrophages,
including high phagocytic activity, increased expression of
leukocyte common antigen (CD45), major histocompati-
bility complex (MHC) class II and costimulatory mole-
cules B7, and secretion of proinflammatory substances
[4]. In addition, phagocytic microglia also participate in
the removal of degenerating neurons and synapses as well
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as Aβ deposits ([5], and reviewed in [6]). Thus, while
some microglial functions are beneficial, the destructive
effects of the production of toxins (such as nitric oxide,
superoxide) and proinflammatory cytokines by activated
microglia apparently overcome the protective functions in
the chronic stage of neuroinflammation [7,8]. In vitro
studies have shown both protection and toxicity contrib-
uted by microglia in response to Aβ depending on the
state of activation of microglia [9,10]. Correlative studies
on AD patients and animal models of AD strongly suggest
that accumulation of reactive microglia at sites of Aβ dep-
osition contributes significantly to neuronal degeneration
[3,11], although decreased microglia have been reported
to be associated with both lowered and enhanced neuro-
degeneration in transgenic animals [12,13]. Aβ itself is
believed to initiate the accumulation and activation of
microglia. However, recent reports provide evidence for
neuron-microglial interactions in regulating CNS inflam-
mation [14]. Nevertheless, the molecular mechanisms
responsible for activation and regulation of microglia
remain to be defined.
Complement proteins have been shown to be associated
with Aβ plaques in AD brains, specifically those plaques
containing the fibrillar form of the Aβ peptide [11]. Com-
plement proteins are elevated in neurodegenerative dis-
eases like AD, Parkinson's disease, and Huntington's
disease as well as more restricted degenerative diseases
such macular degeneration and prion disease [11,15-18].
Microglia, astrocytes, and neurons in the CNS can pro-
duce most of the complement proteins upon stimulation.
C1q, a subcomponent of C1, can directly bind to fibrillar
Aβ and activate complement pathways [19], contributing
to CNS inflammation [13]. In addition, C1q has been
reported to be synthesized by neurons in several neurode-
generative diseases and animal injury models, generally as
an early response to injury [20-23], possibly prior to the
synthesis of other complement components.
Interestingly, C1q and, upon complement activation, C3
also can bind to apoptotic cells and blebs and promote
ingestion of those dying cells [24-26]. Elevated levels of
apoptotic markers are present in AD brain tissue suggest-
ing that many neurons undergo apoptosis in AD [27-29].
Excess glutamate, an excitatory neurotransmitter released
from injured neurons and synapses, is one of the major
factors that perturb calcium homeostasis and induce
apoptosis in neurons [30]. Thus, it is reasonable to
hypothesize that neuronal expression of C1q, as an early
injury response, may serve a potentially beneficial role of
facilitating the removal of apoptotic neurons or neuronal
blebs [31] in diseases thereby preventing excess glutamate
release, excitotoxicity, and the subsequent additional
apoptosis.
We have previously reported that in rat hippocampal slice
cultures treated with exogenous Aβ42, C1q expression
was detected in pyramidal neurons following the internal-
ization of Aβ peptide. This upregulation of neuronal C1q
could be a response to injury from Aβ that would facilitate
removal of dying cells. Concurrently, microglial activa-
tion was prominent upon Aβ treatment. In the present
study, the relationship of Aβ-induced neuronal C1q pro-
duction to microglia activation and Aβ uptake in slice cul-
tures was investigated.
Materials and methods
Materials
Aβ 1–42, obtained from Dr. C. Glabe (UC, Irvine), was
synthesized as previously described [32]. Aβ 10–20 was
purchased from California Peptide Research (Napa, CA).
Lyophilized (in 10 mM HCl) Aβ peptides were solubilized
in H2O and subsequently N-2-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid (HEPES) was added to make a
final concentration of 10 mM HEPES, 500 µM peptide.
This solution was immediately diluted in serum-free
medium and added to slices. Glycine-arginine-glycine-
aspartic acid-serine-proline (RGD) peptide was purchased
from Calbiochem (San Diego, CA). D-(-)-2-amino-5-
phosphonovaleric acid (APV) was purchased from Sigma
(St. Louis, MO). Both compounds were dissolved in ster-
ile Hanks' balanced salt solution (HBSS) without glucose
at 0.2 M and 5 mM, respectively, before diluted in serum-
free medium. Antibodies used in experiments are listed in
Table 1; RT-PCR primers, synthesized by Integrated DNA
Technologies (Coralville, IA), are listed in Table 2. All
other reagents were from Sigma unless otherwise noted.
Table 1: Antibodies used in immunohistochemistry.
antibody/antigen concentration source
anti-rat C1q 2 µg/ml M. Wing, Cambridge, UK
OX-42 (CD11b/c) 5 µg/ml BD/PharMingen, San Diego, CA
ED-1 3 µg/ml Chemicon, Temecula, CA
anti-CD45 0.5 µg/ml Serotec Inc, Raleigh, NC
4G8 (Aβ)1   µg/ml Signet Pathology Systems, Dedham, MA
6E10 (Aβ) 0.5 µg/ml Signet Pathology SystemsJournal of Neuroinflammation 2005, 2:1 http://www.jneuroinflammation.com/content/2/1/1
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Slice cultures
Hippocampal slice cultures were prepared according to
the method of Stoppini et al [33] and as described in Fan
and Tenner [34]. All experimental procedures were carried
out under protocols approved by the University of Cali-
fornia Irvine Institutional Animal Care and Use Commit-
tee. Slices prepared from hippocampi dissected from 10d-
old Sprague Dawley rat pups (Charles River Laboratories,
Inc., Wilmington, MA) were kept in culture for 10 to 11
days before treatment started. All reagents were added to
serum-free medium (with 100 mg/L transferrin and 500
mg/L heat-treated bovine serum albumin) which was
equilibrated at 37°C, 5% CO2 before addition to the
slices. Aβ 1–42 or Aβ 10–20 was added to slice cultures as
described previously [34]. Briefly, peptide was added to
cultures in serum-free medium at 10 or 30 µM. After 7
hours, the peptide was diluted with the addition of an
equal amount of medium containing 20% heat-inacti-
vated horse serum. Fresh peptide was applied for each day
of treatment. Controls were treated the same way except
without peptide. RGD or APV was added to the slice cul-
tures at the same time as Aβ 42.
Immunohistochemistry
At the end of the treatment period, media was removed,
the slices were washed with serum-free media and sub-
jected to trypsinization as previously described [34] for 15
minutes at 4°C to remove cell surface associated, but not
internalized, Aβ. After washing, slices were fixed and cut
into 20 µm sections for immunohistochemistry or
extracted for protein or RNA analysis as described in Fan
and Tenner [34]. Primary antibodies (anti-Aβ antibody
4G8 or 6E10; rabbit anti rat C1q antibody; CD45 (leuko-
cyte common antigen, microglia), OX42 (CD11b/c,
microglia), or ED1 (rat microglia/macrophage marker), or
their corresponding control IgGs were applied at concen-
trations listed in Table 1, followed by biotinylated second-
ary antibody (Vector Labs, Burlingame, CA) and finally
FITC- or Cy3-conjugated streptavidin (Jackson Immu-
noResearch Laboratories, West Grove, PA). Slides were
examined on an Axiovert 200 inverted microscope (Carl
Zeiss Light Microscopy, Göttingen, Germany) with Axio-
Cam (Zeiss) digital camera controlled by AxioVision pro-
gram (Zeiss). Images (of the entire CA1-CA2 region of
hippocampus) were analyzed with KS 300 analysis
program (Zeiss) to obtain the percentage area occupied by
positive immunostaining in a given field.
ELISA
Slices were homogenized in ice-cold extraction buffer (10
mM triethanolamine, pH 7.4, 1 mM CaCl2, 1 mM MgCl2,
0.15 M NaCl, 0.3% NP-40) containing protease inhibitors
pepstatin (2 µg/ml), leupeptin (10 µg/ml), aprotinin (10
µg/ml), and PMSF (1 mM). Protein concentration was
determined by BCA assay (Pierce, Rockford, IL) using BSA
provided for the standard curve.
An ELISA for rat C1q was adapted from Tenner and Volkin
[35] with some modifications as previously described
[34].
RNA preparation and RT-PCR
Total RNA from cultures was isolated using the Trizol rea-
gent (Life Technologies, Grand Island, NY) according to
the manufacturer's instructions. RNA was treated with
RNase-free DNase (Fisher, Pittsburgh, PA) to remove
genomic DNA contamination. Each RNA sample was
extracted from 3 to 5 hippocampal organotypic slices in
the same culture insert. The reverse transcription (RT)
reaction conditions were 42°C for 50 min, 70°C for 15
min. Tubes were then centrifuged briefly and held at 4°C.
Primer sequences and PCR conditions are listed in Table
2. PCR products were electrophoresed in 2% agarose gel
in TAE buffer and visualized with ethidium bromide
luminescence. To test for differences in total RNA concen-
tration among samples, mRNA level for rat β-actin were
also determined by RT-PCR. Results were quantified using
NIH image software [36] by measuring DNA band
Table 2: PCR primers and cycling conditions for RT-PCR assay.
Gene Primer sequences Denaturation Annealing Extension cycle Ref
C1qB 5'-cgactatgcccaaaacacct-3'
5'-ggaaaagcagaaagccagtg-3'
94°C 1 min 60°C 1 min30 sec 72°C 2 min 35 [61]
MCSF 5'-ccgttgacagaggtgaacc-3'
5'-tccacttgtagaacaggaggc-3'
92°C 30 sec 58°C 1 min 72°C 1 min30 sec 35 [62]
CD40 5'-cgctatggggctgcttgttgacag-3'
5'-gacggtatcagtggtctcagtggc-3'
94°C 30 sec 58°C30 sec 72°C 1 min 30 [63]
β-actin 5'-ggaaatcgtgcgtgacatta-3'
5'-gatagagccaccaatccaca-3'
94°C 30 sec 60°C30 sec 72°C 1 min 25 [61]
IL-8 5'-gactgttgtggcccgtgag-3'
5'-ccgtcaagctctggatgttct-3'
94°C 1 min 56°C 1 min 72°C 1 min 39 [64]Journal of Neuroinflammation 2005, 2:1 http://www.jneuroinflammation.com/content/2/1/1
Page 4 of 13
(page number not for citation purposes)
intensity from digital images taken on GelDoc (BIO-RAD)
with Quantity One program.
Results
NMDA receptor antagonist APV inhibits Aβ42 uptake and 
Aβ42-induced microglial activation and neuronal C1q 
production
We have previously reported that C1q was detected in
cells positive for neuronal markers and that microglial
cells were activated in slices following Aβ42 ingestion
[34]. Lynch and colleagues have shown that APV, a spe-
cific NMDA glutamate receptor antagonist, was able to
block Aβ42 uptake by hippocampal neurons in slice cul-
tures [37]. This provided a mechanism to down-modulate
the Aβ42 internalization and test the effect on induction
of C1q synthesis in neurons. Slices were treated with no
peptide, 50 µM APV, 30 µM Aβ42, or 30 µM Aβ42 + 50 µM
APV for 3 days with fresh reagents added daily. Cultures
were collected and processed as described in Materials and
Methods. Similar to reported previously, addition of exog-
enous Aβ42 resulted in Aβ uptake by hippocampal neu-
rons, induction of C1q synthesis in neurons, and
activation of microglial cells (Figure 1d, e, f compared
with 1a, b, c). As anticipated, Aβ42 uptake in neurons
detected by both 4G8 (Figure 1g) and 6E10 (data not
shown) was inhibited by APV co-treatment. Neuronal
C1q immunoreactivity was also inhibited when APV was
added to Aβ42 treated slices (Figure 1h). Aβ42-triggered
microglial activation, assessed by upregulation of antigens
detected by anti-CD45 (Figure 1i vs. 1f), OX42 and ED1
(data not shown) was also fully diminished by APV. To
quantify the immunohistochemistry results, images were
taken from the entire CA1-CA2 region of each immunos-
tained hippocampal section and averaged. Image analysis
further substantiated the reduction in Aβ uptake, C1q syn-
thesis and microglial activation (Figure 1j). C1q gene
expression at mRNA and protein levels was also assessed
by RT-PCR and ELISA, respectively. Results showed
decrease of C1q mRNA and protein in slice extracts treated
with 30 µM Aβ42 + APV, compared to 30 µM Aβ42 alone
(Figure 2a and 2b, n = 2).
Integrin receptor antagonist GRGDSP (RGD) peptide 
enhances Aβ42 uptake and Aβ42-induced microglial 
activation and neuronal C1q expression
It has been shown that an integrin receptor antagonist
peptide, GRGDSP (RGD), can enhance Aβ ingestion by
neurons in hippocampal slice cultures [37]. Therefore, we
adopted this experimental manipulation as an alternative
approach to modulate the level of Aβ uptake in neurons
and assess the correlation between Aβ ingestion and neu-
ronal C1q expression. Slices were treated with no peptide,
2 mM RGD, 10 µM Aβ42, or 10 µM Aβ42 + 2 mM RGD
for 3 days with fresh peptides added daily. At the end of
treatments, slices were collected and processed.
Addition of RGD peptide by itself did not result in neuro-
nal C1q induction or microglial activation (CD45) com-
pared to no treatment control, as assessed by
immunostaining (data not shown). While greater inges-
tion was seen at 30 µM (Figure 1d, e, f), addition of 10 µM
Aβ shows detectable Aβ ingestion, C1q expression, and
microglial activation (Figure 3d, e, f compared with 3a, b,
c). The lower concentration of Aβ was chosen for these
experiments to ensure the detection of potentiation of
uptake (vs. a saturation of uptake at higher Aβ42 concen-
trations). When RGD was provided in addition to 10 µM
Aβ42, Aβ immunoreactivity in neurons with antibody
4G8 (Figure 3g vs. 3d) and 6E10 (similar results, data not
shown), neuronal C1q expression (Figure 3h vs. 3e), and
CD45 (Figure 3i vs. 3f) upregulation in microglia trig-
gered by Aβ42, were significantly enhanced. Enhanced
microglial activation was also detected with OX42 and
ED1 antibodies (data not shown). Quantification by
image analysis (Figure 3j) definitively demonstrated that
the increased accumulation of Aβ in neurons, microglial
activation, and induction of neuronal C1q synthesis in
the presence of RGD. RT-PCR (Figure 4a) and ELISA (Fig-
ure 4b) further demonstrated that both mRNA and pro-
tein expression of C1q was enhanced by RGD. Thus,
under the conditions tested, both neuronal C1q synthesis
and microglial activation are coordinately affected when
the internalization of Aβ is modulated negatively by APV
or positively by RGD.
Aβ10–20 blocks Aβ42 induced microglial activation but 
triggers C1q synthesis in hippocampal neurons
Data reported by Giulian et al suggests that residues 13–
16, the HHQK domain in human Aβ peptide, mediate Aβ-
microglia interaction [38]. To investigate the effect of
HHQK peptides in this slice culture system, rat hippocam-
pal slices were treated with no peptide, 10 µM Aβ42, 10
µM Aβ42 + 30 µM Aβ10–20, or 30 µM Aβ10–20 for 3 days
with fresh peptides added daily. Sections were immunos-
tained for Aβ, C1q, and microglia. Aβ immunoreactivity
was significantly reduced in the Aβ42 +Aβ10–20 treated
tissues compared to the Aβ42 alone treatment (Figure 5g
vs. 5d). Aβ10–20 alone-treated slices lacked detectable
immunopositive cells with either 4G8 or 6E10 anti-Aβ
antibody (Figure 5j and data not shown). Furthermore, as
anticipated [38], when Aβ10–20 was present, microglial
activation by Aβ42 as assessed by level of CD45, OX42,
and ED1, was significantly reduced (Figure 5i vs. 5f and
data not shown). Image analysis confirmed the inhibition
of Aβ uptake (Figure 5m, open bars) and microglial acti-
vation (Figure 5m, striped bars) by the HHQK-containing
Aβ10–20 peptide. However, production of C1q in neu-
rons treated with Aβ42 was not inhibited by Aβ10–20
(Figure 5h vs. 5e). In fact, with Aβ10–20 alone, neurons
were induced to express C1q to a similar level as Aβ42
(Figure 5k). The sustained C1q induction by Aβ10–20 wasJournal of Neuroinflammation 2005, 2:1 http://www.jneuroinflammation.com/content/2/1/1
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APV inhibited Aβ uptake, neuronal C1q production, and microglial activation Figure 1
APV inhibited Aβ uptake, neuronal C1q production, and microglial activation. Slices were treated with no peptide (a, b, c), 30 
µM Aβ 42 (d, e, f), or 30 µM Aβ 42 + 50 µM APV (g, h, i) for 3 days with fresh reagents added daily. Immunohistochemistry for 
Aβ (4G8, a, d, g), C1q (anti-rat C1q, b, e, h), and microglia (CD45, c, f, i) was performed on fixed and sectioned slices. Scale bar 
= 50 µm. Results are representative of three separately performed experiments. j. Immunoreactivity of Aβ (open bar), C1q 
(black bar), or CD45 (striped bar) was quantified as described in Materials and Methods. Values are the mean ± SD (error 
bars) from images taken from 8 slices (2 sections per slice) in 3 independent experiments (* p < 0.0001 compared to Aβ, 
Anova single factor test).Journal of Neuroinflammation 2005, 2:1 http://www.jneuroinflammation.com/content/2/1/1
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confirmed by RT-PCR for C1q with mRNAs extracted from
slices (Figure 6a).
CD40, IL-8, and MCSF mRNAs are induced by Aβ42 and 
differentially regulated by Aβ10–20 and APV
It is known that activated microglia cells can produce pro-
inflammatory cytokines, chemokines, and nitric oxide, as
well as higher expression of co-stimulatory molecules like
CD40 and B7 [39]. Many of those proteins have been
shown to be upregulated in microglia stimulated by Aβ in
cell culture and in vivo [40]. Semi-quantitative reverse
transcriptase PCR technique was used to determine how
certain inducible activation products were modified in
slice cultures stimulated with exogenous Aβ42 and in the
presence of Aβ10–20 or APV. Rat slices were treated with
30 µM Aβ42 +/-APV or 10 µM Aβ42 +/- 30 µM Aβ10–20
for 3 days before mRNAs were extracted from tissues. LPS,
was added at 150 ng/ml for 24 hr, served as positive con-
trol, with positive detection for all molecules tested (data
not shown).
RT-PCR revealed that mRNAs for CD40 and IL-8 were
enhanced in Aβ treated slice cultures relative to the con-
trol after 3 days (Figure 6a and 6b). Both Aβ10–20 and
APV inhibited Aβ42-triggered upregulation of CD40 (Fig-
ure 6a and 6b), consistent with the inhibition of micro-
glial activation by both Aβ10–20 and APV assessed by
immunohistochemistry. APV also blocked Aβ42-induced
IL-8 expression (Figure 6b), as did Aβ10–20 (data not
shown).
Macrophage-colony stimulating factor (MCSF), a proin-
flammatory mediator for microglial proliferation and
activation, has been shown to be expressed by neurons
upon Aβ stimulation [41]. The expression of MCSF was
induced in slice culture by Aβ treatment by Day 3 (Figure
6a and 6b) and this increase was blocked by the presence
of APV (Figure 6b). In contrast, Aβ10–20 did not alter the
Aβ42-triggered MCSF induction (Figure 6a), suggesting
that MCSF may be required for microglial activation, but
alone is not sufficient to induce that activation.
Discussion
Previously, it has been shown that Aβ is taken up by
pyramidal neurons in hippocampal slice culture and that
the synthesis of complement protein C1q is induced in
neurons [34]. Here we demonstrate that blocking of Aβ42
accumulation in neurons by NMDA receptor antagonist
APV and increasing Aβ42 ingestion by integrin antagonist
RGD is accompanied by inhibition and elevation in neu-
ronal C1q expression, respectively. However, Aβ10–20,
which markedly inhibits Aβ42 accumulation in
pyramidal neurons, does not have any inhibitory effect on
neuronal C1q expression. Thus, intraneuronal accumula-
tion of Aβ is not necessary for Aβ-mediated induction of
neuronal C1q synthesis.
Since Aβ10–20 alone can induce a level of C1q expression
in neurons comparable to Aβ42, it is hypothesized that
amino acids 10–20 in Aβ peptide contain the sequence
that is recognized by at least one Aβ receptor. It was
reported by Giulian et al. that the HHQK domain (resi-
dues 13–16) in Aβ is critical for Aβ-microglia interaction
and activation of microglia, as they demonstrated that
small peptides containing HHQK suppress microglial
activation and Aβ-induced microglial mediated neurotox-
icity [38]. We have previously reported that rat Aβ42,
which differs in 3 amino acids from human Aβ42, includ-
ing 2 in the 10–20 region and 1 in the HHQK domain,
was internalized and accumulated in neurons but failed to
induce neuronal C1q expression [34]. This is consistent
with the hypothesis that a specific Aβ interaction (either
Inhibition of Aβ-induced C1q synthesis by APV Figure 2
Inhibition of Aβ-induced C1q synthesis by APV. a. C1q and β-
actin mRNAs were assessed by RT-PCR in slices after 3 days 
of no peptide, 30 µM Aβ, or 30 µM Aβ + 50 µM APV treat-
ment. Results are from one experiment representative of 
two independent experiments. b. Slices were treated with no 
peptide (open bar), 30 µM Aβ (black bar), or 30 µM Aβ + 50 
µM APV (striped bar) daily for 3 days. 3 or 4 slices that had 
received same treatment were pooled, extracted and pro-
teins analyzed by ELISA. Data are presented as percentage of 
control in ng C1q/mg total protein (mean ± SD of three inde-
pendent experiments, **p = 0.01 compared to Aβ, one-tailed 
paired t-test).Journal of Neuroinflammation 2005, 2:1 http://www.jneuroinflammation.com/content/2/1/1
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RGD enhanced Aβ uptake, neuronal C1q expression, and microglial activation Figure 3
RGD enhanced Aβ uptake, neuronal C1q expression, and microglial activation. Hippocampal slices were treated with no pep-
tide (a, b, c), 10 µM Aβ 42 (d, e, f), or 10 µM Aβ 42 + 2 mM RGD (g, h, i) for 3 days with fresh peptides added daily. Immuno-
histochemistry for Aβ (4G8, a, d, g), C1q (anti-rat C1q, b, e, h), and microglia (CD45, c, f, i) was performed on fixed slice 
sections. Scale bar = 50 µm. Results are representative of three separately performed experiments. j. Immunoreactivities of Aβ 
(open bar), C1q (black bar), or CD45 (striped bar) were quantified as described in Materials and Methods. Values are the mean 
± SD (error bars) from images taken from 8 slices (2 sections per slice) in 3 independent experiments (* p < 0.0001, compared 
to Aβ, Anova single factor test).Journal of Neuroinflammation 2005, 2:1 http://www.jneuroinflammation.com/content/2/1/1
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neuronal or microglial), presumably via the HHQK
region of the Aβ peptide, but not intracellular Aβ accumu-
lation, can lead to neuronal C1q induction in hippocam-
pal neurons.
Neurons are the major type of cells that accumulate exog-
enous Aβ in slice cultures. Microglial activation, as
assessed by CD45, OX42, and ED1, was increased with
enhanced neuronal Aβ42 uptake and inhibited when
Aβ42 uptake was blocked by APV or Aβ10–20 in this slice
culture system. These data would be consistent with a
model in which neurons, upon internalization of Aβ pep-
tide, secrete molecules to modulate microglial activation
[14,41,42] (Figure 7, large arrows). Synthesis and release
of those molecules may require the intracellular accumu-
lation of Aβ since blocking intraneuronal Aβ accumula-
tion always blocked microglial activation. The finding
that treatment with Aβ10–20 alone did not result in
intraneuronal Aβ immunoreactivity or microglial activa-
tion, while rat Aβ42, which did accumulate within neu-
rons, induced activation of microglial cells, is consistent
with this hypothesis. It should be noted that an absence of
Aβ immunoreactivity in Aβ10–20 treated slices does not
exclude the possibility that Aβ10–20 was ingested but
soon degraded by cells, and thus accumulation of Aβ
rather than ingestion alone may be necessary to induce
secretion of microglia activating molecules from neurons.
Giulian et al. reported that the HHQK region alone was
not able to activate microglia [38]. Thus, Aβ10–20 might
block microglial activation by competing with Aβ42 for
direct microglial binding, as well as by blocking uptake
and accumulation of Aβ in neurons.
Activated glial cells, especially microglia, are major players
in the neuroinflammation seen in of Alzheimer's disease
[43]. Microglial cells can be activated by Aβ and produce
proinflammatory cytokines, nitric oxide, superoxide, and
other potentially neurotoxic substances in vitro, although
the state of differentiation/ activation of microglia and the
presence of other modulating molecules is known to
influence this stimulation [7,9,43]. "Activated" microglia
also become more phagocytic and can partially ingest and
degrade amyloid deposits in brain. This leads many to
hypothesize that there are multiple subsets of "activated"
microglia, each primed to function in a specific but dis-
tinct way [5,43].
In hippocampal slice cultures, we and others have shown
that Aβ42 triggered microglial activation as assessed by
immunohistochemical detection of CR3 (OX42), and
cathepsin D [34,37]. Several chemokines, including
macrophage inflammatory protein-1 (MIP-1α, MIP-1β),
monocyte chemotactic protein (MCP-1), and interleukin
8 (IL-8), have been reported to increase in Alzheimer's dis-
ease patients or cell cultures treated with Aβ [44,45].
CD40, a co-stimulatory molecule, is also upregulated in
Aβ-treated microglia [10]. In this study, similar to reports
of cultured microglia, immunoreactivity of CD45 was
found increased on microglia in Aβ42 treated slice cul-
tures, and CD40 and IL-8 messenger RNAs were elevated
after Aβ42 exposure. As expected, CD40 and IL-8 mRNA
induction was blocked whenever immunohistochemistry
analysis showed the inhibition of microglial activation.
[We did not observe change in MIP-1α, 1β mRNAs in slice
culture with Aβ42 treatment, and MCP-1 was too low to
be detected with or without Aβ stimulation although it
was detectable in LPS treated slices (data not shown).]
The data presented thus far suggest the hypothesis that
neurons, upon uptake and accumulation of Aβ, release
certain substances that activate microglia. One possible
candidate of those neuron-produced substances is MCSF,
which has been reported to be induced in neuronal cul-
Enhancement of Aβ-induced C1q synthesis by RGD Figure 4
Enhancement of Aβ-induced C1q synthesis by RGD. a. C1q 
and β-actin mRNAs were assessed by RT-PCR in slices after 
3 days of no peptide, 10 µM Aβ, or 10 µM Aβ + 2 mM RGD 
treatment. Results are from one experiment representative 
of two independent experiments. b. Slices were treated with 
no peptide (open bar), 10 µM Aβ (black bar), or 10 µM Aβ + 
2 mM RGD (striped bar) daily for 3 days. 3 or 4 slices that 
had received same treatment were pooled, extracted and 
proteins analyzed by ELISA. Data are presented as percent-
age of control in ng C1q/mg total protein (mean ± SD of 
three independent experiments, **p = 0.06 compared to Aβ, 
one-tailed paired t-test).Journal of Neuroinflammation 2005, 2:1 http://www.jneuroinflammation.com/content/2/1/1
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Aβ10–20 blocked Aβ42 uptake, microglial activation, but not neuronal C1q induction Figure 5
Aβ10–20 blocked Aβ42 uptake, microglial activation, but not neuronal C1q induction. Slices were treated with no peptide (a, 
b, c), 10 µM Aβ 42 (d, e, f), 10 µM Aβ 42 + 30 µM Aβ 10–20 (g, h, i) or 30 µM Aβ 10–20 (j, k, l) for 3 days with fresh peptides 
added daily. Immunohistochemistry for Aβ (4G8, a, d, g, j), C1q (anti-rat C1q, b, e, h, k), and microglia (CD45, c, f, i, l) was per-
formed on fixed and sectioned slices. Results are representative of three independent experiments. Scale bar = 50 µm. m. 
Immunoreactivities of Aβ (open bar), C1q (black bar), or CD45 (striped bar) were quantified as described in Materials and 
Methods. Values are the mean ± SD (error bars) from images taken from 8 slices (2 sections per slice) in 3 independent exper-
iments. Microglial activation by Aβ42 was significantly inhibited by Aβ10–20 (* p < 0.0001, compared to either Aβ42 + Aβ10–
20 or Aβ10–20, Anova single factor test).Journal of Neuroinflammation 2005, 2:1 http://www.jneuroinflammation.com/content/2/1/1
Page 10 of 13
(page number not for citation purposes)
tures upon Aβ stimulation [41,46], and is known to be
able to trigger microglial activation [47]. Indeed, MCSF
mRNA was found to increase after 3 days of Aβ treatment
(Figure 6a and 6b). The diminished MCSF signal with the
addition of APV and coordinate lack of microglial activa-
tion is consistent with a proposed role of activating micro-
glia by MCSF produced by stimulated neurons. However,
in the presence of Aβ10–20, MCSF induction was unal-
tered, though microglial activation was inhibited. Thus,
MCSF alone does not lead to the upregulation of the
above-mentioned microglial activation markers.
In this organotypic slice culture, no significant neuronal
damage was observed in 3 day treatment with Aβ at con-
centrations that have been reported to cause neurotoxicity
in cell cultures. One possible explanation is that the pep-
tide has to penetrate the astrocyte layer surrounding the
tissue to reach the multiple layers of neurons. Thus, the
effective concentration of Aβ on neurons is certainly much
lower than the added concentration. Aβ failing to induce
neurotoxicity in slices to the same extent as in cell cultures
may also indicate the loss of certain protective
mechanisms in isolated cells. A distinct advantage of the
slice culture model is that the tissue contains all of the cell
types present in brain, the cells are all at the same devel-
opmental stage, and cells may communicate in similar
fashion as in vivo.
Our data demonstrating distinct pathways for the induc-
tion of neuronal C1q and the activation of microglial by
amyloid peptides suggest the involvement of multiple Aβ
receptors on multiple cell types in response to Aβ (Figure
7, model) and possibly in Alzheimer's disease progres-
sion. This multiple-receptor mechanism is supported by
reports suggesting many proteins/complexes can mediate
the Aβ interaction with cells [48]. These include, but not
limited to, the alpha7nicotinic acetylcholine receptor
(alpha7nAChR), the P75 neurotrophin receptor
(P75NTR) on neurons, the scavenger receptors and
heparan sulfate proteoglycans on microglia, as well as
receptor for advanced glycosylation end-products (RAGE)
and integrins on both neurons and microglia (Figure 7).
Several signaling pathways have been implicated in spe-
cific Aβ-receptor interactions [49-51]. However, it is not
known which receptors are required for induction of C1q
in neurons. In addition, as of yet the function of neuronal
C1q has not been determined. Previous reports from our
lab have shown that C1q is associated with hippocampal
neurons in AD cases but not normal brain [52], and the
fact that it is synthesized by the neurons has been docu-
mented by others [23,53]. In addition, C1q was promi-
nently expressed in a preclinical case of AD (significant
diffuse amyloid deposits, with no plaque associated C1q,
and no obvious cognitive disorder) and is expressed in
other situations of "stress" or injury in the brain [54-58].
Indeed, overexpression of human cyclooxygenase-2 in
mice leads to C1q synthesis in neurons and inhibition of
COX-2 activity abrogates C1q induction. These data sug-
gest that in addition to the facilitation of phagocytosis by
microglia [59,60] (particularly of dead cells or neuronal
blebs), the induction of C1q may be an early response of
neurons to injury or regulation of an inflammatory
response, consistent with a role in the progression of neu-
rodegeneration in AD. Whether and how the neuronal
C1q production affects the survival of neurons is still
under investigation. Identifying the receptors responsible
a. Aβ10–20 inhibited Aβ42-induced C1q and CD40 mRNA  elevation, but not that of MCSF Figure 6
a. Aβ10–20 inhibited Aβ42-induced C1q and CD40 mRNA 
elevation, but not that of MCSF. C1q, MCSF, CD40, and β-
actin mRNAs were assessed by RT-PCR in slices treated for 
3 days with no peptide, 10 µM Aβ 42, 30 µM Aβ 10–20, or 
10 µM Aβ 42 + 30 µM Aβ 10–20. Results are from one 
experiment representative of two independent experiments. 
b. APV blocked MCSF, CD40, and IL-8 mRNA induction trig-
gered by Aβ42. RT-PCR for MCSF, CD40, IL-8, and β-actin 
were performed on RNA extracted from slices treated with 
no peptide (control), 30 µM Aβ 42, or 30 µM Aβ42 + 50 µM 
APV for 3 days. Results are from one experiment represent-
ative of two separate experiments.Journal of Neuroinflammation 2005, 2:1 http://www.jneuroinflammation.com/content/2/1/1
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for neuronal C1q induction may be informative in under-
standing the role of C1q in neurons in injury and disease.
Conclusions
In summary, induction of C1q expression in hippocampal
neurons by exogenous Aβ42 is dependent upon specific
cellular interactions with Aβ peptide that require HHQK
region-containing sequence, but does not require
intraneuronal accumulation of Aβ or microglial activa-
tion. Thus, induction of neuronal C1q synthesis may be
an early response to injury to facilitate clearance of dam-
aged cells, while modulating inflammation and perhaps
facilitating repair. Microglial activation in slice culture
involves the induction of CD45, CD40, CR3, and IL-8,
which correlates with intraneuronal accumulation of Aβ,
indicating contribution of factors released by neurons
upon Aβ exposure. MCSF may be one of those stimulatory
factors, though by itself MCSF cannot fully activate
microglia.
Removal of Aβ to prevent deposition and of cellular
debris to avoid excitotoxicity would be a beneficial role of
microglial activation in AD. However, activated microglia
also produce substances that are neurotoxic. Therefore,
Model of Aβ interaction with neurons and microglia in slice cultures Figure 7
Model of Aβ interaction with neurons and microglia in slice cultures. Exogenous Aβ peptide interacts with neuronal receptors 
leads to at least two separate consequences, in one of which C1q expression is upregulated in neurons. A second receptor 
mediates the secretion of certain modulatory molecules, which lead to microglial activation involving the expression of CD45, 
CR3, CD40, and IL-8. This does not exclude the direct interactions of Aβ with receptor(s) on microglia that may also contrib-
ute to microglial activation.
neuron microglia
Aβ β β β
Aβ β β β receptors
IL-8
C1q
neuronal Aβ β β β receptors:
α α α α7-nicotinic receptor
neurotrophin receptor
?
microglial Aβ β β β receptors:
scavenger receptors
heparan sulfate proteoglycans
?Journal of Neuroinflammation 2005, 2:1 http://www.jneuroinflammation.com/content/2/1/1
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the goal of modulating the inflammatory response in neu-
rodegenerative diseases like AD is to enhance the phago-
cytic function of glial cells and inhibit the production of
proinflammatory molecules. Being able to distinguish in
the slice system C1q expression (which has been shown to
facilitate phagocytosis of apoptotic cells in other systems
[24]) from microglial activation suggests a plausible
approach to reach that goal in vivo.
List of abbreviations
Aβ: amyloid beta; AD: Alzheimer's disease; APV: D-(-)-2-
amino-5-phosphonovaleric acid; BSA: bovine serum
albumin; GRGDSP (RGD): glycine-arginine-glycine-
aspartic acid-serine-proline; HBSS: Hanks' balanced salt
solution; HEPES: N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid; MCSF: macrophage colony stimulat-
ing factor; NMDA: N-methyl-D-aspartic acid; PMSF: phe-
nylmethylsulfonylfluoride; TAE: triethanolamine.
Competing interests
The author(s) declare that they have no competing
interests.
Authors' contributions
RF cultured and processed the tissue, performed all exper-
iments (immunohistochemistry, ELISA, PCR and others),
analyzed the data, and drafted the manuscript. AJT con-
tributed to the design of the study, guided data interpreta-
tion and presentation and edited the manuscript.
Acknowledgments
This work is supported by NIH NS 35144 and P50 AG16573. The authors 
thank Dr. Saskia Milton and Dr. Charles Glabe for providing the synthetic 
human Aβ peptide, and Dr. Maria Fonseca, Dr. Ming Li, and Karntipa Pis-
alyaput for their review of this manuscript.
References
1. Mattson MP: Pathways towards and away from Alzheimer's
disease. Nature 2004, 430:631-639.
2. Webster SD, Yang AJ, Margol L, Garzon-Rodriguez W, Glabe CG,
Tenner AJ: Complement component C1q modulates the
phagocytic behavior of microglia. Exp Neurol 2000, 161:127-138.
3. Rogers J, Strohmeyer R, Kovelowski CJ, Li R: Microglia and inflam-
matory mechanisms in the clearance of amyloid beta
peptide. Glia 2002, 40:260-269.
4. Nelson PT, Soma LA, Lavi E: Microglia in diseases of the central
nervous system. Ann Med 2002, 34:491-500.
5. Petersen MA, Dailey ME: Diverse microglial motility behaviors
during clearance of dead cells in hippocampal slices. Glia 2004,
46:195-206.
6. D'Andrea MR, Cole GM, Ard MD: The microglial phagocytic role
with specific plaque types in the Alzheimer disease brain.
Neurobiol Aging 2004, 25:675-683.
7. Combs CK, Karlo JC, Kao SC, Landreth GE: beta-Amyloid stimu-
lation of microglia and monocytes results in TNFalpha-
dependent expression of inducible nitric oxide synthase and
neuronal apoptosis. J Neurosci 2001, 21:1179-1188.
8. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ: Early
inflammation and dementia: a 25-year follow-up of the
Honolulu-Asia Aging Study. Ann Neurol 2002, 52:168-174.
9. Li M, Pisalyaput K, Galvan M, Tenner AJ: Macrophage colony stim-
ulatory factor and interferon-gamma trigger distinct mech-
anisms for augmentation of beta-amyloid-induced microglia-
mediated neurotoxicity. J Neurochem 2004, 91:623-633.
10. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Fla-
vell RA, Mullan M: Microglial activation resulting from CD40-
CD40L interaction after β-amyloid stimulation. Science 1999,
286:2352-2355.
11. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper
NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S,
Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie
IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C,
Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van
Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B,
Wenk G, Wyss-Coray T: Inflammation and Alzheimer's
disease. Neurobiol Aging 2000, 21:383-421.
12. Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L,
Masliah E, Mucke L: TGF-beta1 promotes microglial amyloid-
beta clearance and reduces plaque burden in transgenic
mice. Nat Med 2001, 7:612-618.
13. Fonseca MI, Zhou J, Botto M, Tenner AJ: Absence of C1q leads to
less neuropathology in transgenic mouse models of Alzhe-
imer's disease. J Neurosci 2004, 24:6457-6465.
14. Mott RT, Ait-Ghezala G, Town T, Mori T, Vendrame M, Zeng J,
Ehrhart J, Mullan M, Tan J: Neuronal expression of CD22: novel
mechanism for inhibiting microglial proinflammatory
cytokine production. Glia 2004, 46:369-379.
15. McGeer PL, McGeer EG: Inflammation and neurodegeneration
in Parkinson's disease. Parkinsonism Relat Disord 2004, 10(Suppl
1):S3-S7.
16. Singhrao SK, Neal JW, Morgan BP, Gasque P: Increased comple-
ment biosynthesis by microglia and complement activation
on neurons in Huntington's disease.  Exp Neurol 1999,
159:362-376.
17. Johnson LV, Leitner WP, Staples MK, Anderson DH: Complement
activation and inflammatory processes in Drusen formation
and age related macular degeneration.  Exp Eye Res 2001,
73:887-896.
18. Kovacs GG, Gasque P, Strobel T, Lindeck-Pozza E, Strohschneider M,
Ironside JW, Budka H, Guentchev M: Complement activation in
human prion disease. Neurobiol Dis 2004, 15:21-28.
19. Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ: β-amyloid
activates complement by binding to a specific region of the
collagen-like domain of the C1q A chain.  J Immunol 1994,
152:5050-5059.
20. Huang J, Kim LJ, Mealey R, Marsh JrHC, Zhang Y, Tenner AJ, Connolly
ES Jr, Pinsky DJ: Neuronal protection in stroke by an sLex-gly-
cosylated complement inhibitory protein.  Science 1999,
285:595-599.
21. Terai K, Walker DG, McGeer EG, McGeer PL: Neurons express
proteins of the classical complement pathway in Alzheimer
disease. Brain Res 1997, 769:385-390.
22. Shen Y, Li R, McGeer EG, McGeer PL: Neuronal expression of
mRNAs for complement proteins of the classical pathway in
Alzheimer brain. Brain Res 1997, 769:391-395.
23. Rozovsky I, Morgan TE, Willoughby DA, Dugich-Djordjevich MM,
Pasinetti GM, Johnson SA, Finch CE: Selective expression of Clus-
terin (SGP-2) and complement C1qB and C4 during
responses to neurotoxins in vivo and in vitro.  Neuroscience
1994, 62:741-758.
24. Botto M, Dell'agnola C, Bygrave AE, Thompson EM, Cook HT, Petry
F, Loos M, Pandolfi PP, Walport MJ: Homozygous C1q deficiency
causes glomerulonephritis associated with multiple apop-
totic bodies. Nat Genet 1998, 19:56-59.
25. Mevorach D, Mascarenhas JO, Gershov D, Elkon KB: Complement-
dependent clearance of apoptotic cells by human
macrophages. J Exp Med 1998, 188:2313-2320.
26. Ogden CA, deCathelineau A, Hoffmann PR, Bratton D, Ghebrehiwet
B, Fadok VA, Henson PM: C1q and mannose binding lectin
engagement of cell surface calreticulin and CD91 initiates
macropinocytosis and uptake of apoptotic cells. J Exp Med
2001, 194:781-796.
27. Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ: Gene
expression profiling of 12633 genes in Alzheimer hippocam-
pal CA1: transcription and neurotrophic factor down-regula-
tion and up-regulation of apoptotic and pro-inflammatory
signaling. J Neurosci Res 2002, 70:462-473.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Neuroinflammation 2005, 2:1 http://www.jneuroinflammation.com/content/2/1/1
Page 13 of 13
(page number not for citation purposes)
28. Guo H, Albrecht S, Bourdeau M, Petzke T, Bergeron C, LeBlanc AC:
Active caspase-6 and caspase-6-cleaved tau in neuropil
threads, neuritic plaques, and neurofibrillary tangles of
Alzheimer's disease. Am J Pathol 2004, 165:523-531.
29. Jo DG, Lee JY, Hong YM, Song S, Mook-Jung I, Koh JY, Jung YK:
Induction of pro-apoptotic calsenilin/DREAM/KChIP3 in
Alzheimer's disease and cultured neurons after amyloid-
beta exposure. J Neurochem 2004, 88:604-611.
30. Michaelis EK: Molecular biology of glutamate receptors in the
central nervous system and their role in excitotoxicity, oxi-
dative stress and aging. Prog Neurobiol 1998, 54:369-415.
31. Lesort M, Terro F, Esclaire F, Hugon J: Neuronal APP accumu-
lates in toxic membrane blebbings.  J Neural Transm 1997,
104:497-513.
32. Kagan BL, Hirakura Y, Azimov R, Azimova R, Lin MC: The channel
hypothesis of Alzheimer's disease: current status.  Peptides
2002, 23:1311-1315.
33. Stoppini L, Buchs PA, Muller D: A simple method for organotypic
cultures of nervous tissue. J Neurosci Methods 1991, 37:173-182.
34. Fan R, Tenner AJ: Complement C1q expression induced by
Abeta in rat hippocampal organotypic slice cultures.  Exp
Neurol 2004, 185:241-253.
35. Tenner AJ, Volkin DB: Complement subcomponent C1q
secreted by cultured human monocytes has subunit struc-
ture identical with that of serum C1q.  Biochem J 1986,
233:451-458.
36. NIH image 2004 [http://rsb.info.nih.gov/nih-image/download.html].
37. Bi X, Gall CM, Zhou J, Lynch G: Uptake and pathogenic effects
of amyloid beta peptide 1–42 are enhanced by integrin
antagonists and blocked by NMDA receptor antagonists.
Neuroscience 2002, 112:827-840.
38. Giulian D, Haverkamp LJ, Yu JH, Karshin M, Tom D, Li J, Kazanskaia
A, Kirkpatrick J, Roher AE: The HHQK domain of β-amyloid
provides a structural basis for the immunopathology of
Alzheimer's disease. J Biol Chem 1998, 273:29719-29726.
39. Aloisi F: Immune function of microglia. Glia 2001, 36:165-179.
40. Meda L, Baron P, Scarlato G: Glial activation in Alzheimer's dis-
ease: the role of Abeta and its associated proteins. Neurobiol
Aging 2001, 22:885-893.
41. Yan SD, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW, Rajavashisth
T, Chen X, Godman GC, Stern D, Schmidt AM: Amyloid-β pep-
tide-receptor for advanced glycation endproduct interaction
elicits neuronal expression of macrophage-colony
stimulating factor: a proinflammatory pathway in Alzheimer
disease. Proc Natl Acad Sci U S A 1997, 94:5296-5301.
42. Neumann H, Wekerle H: Neuronal control of the immune
response in the central nervous system: linking brain immu-
nity to neurodegeneration. J Neuropathol Exp Neurol 1998, 57:1-9.
43. Streit WJ: Microglia and Alzheimer's disease pathogenesis. J
Neurosci Res 2004, 77:1-8.
44. Nagai A, Nakagawa E, Hatori K, Choi HB, McLarnon JG, Lee MA, Kim
SU: Generation and characterization of immortalized human
microglial cell lines: expression of cytokines and
chemokines. Neurobiol Dis 2001, 8:1057-1068.
45. Lee YB, Nagai A, Kim SU: Cytokines, chemokines, and cytokine
receptors in human microglia. J Neurosci Res 2002, 69:94-103.
46. Lue LF, Walker DG, Rogers J: Modeling microglial activation in
Alzheimer's disease with human postmortem microglial
cultures. Neurobiol Aging 2001, 22:945-956.
47. Imai Y, Kohsaka S: Intracellular signaling in M-CSF-induced
microglia activation: role of Iba1. Glia 2002, 40:164-174.
48. Verdier Y, Zarandi M, Penke B: Amyloid beta-peptide interac-
tions with neuronal and glial cell plasma membrane: binding
sites and implications for Alzheimer's disease. J Pept Sci 2004,
10:229-248.
49. Combs CK, johnson DE, Cannady SB, Lehman TM, Landreth GE:
Identification of microglial signal transduction pathways
mediating a neurotoxic response to amyloidogenic frag-
ments of β-amyloid and prion proteins.  J Neurosci 1999,
19:928-939.
50. McDonald DR, Brunden KR, Landreth GE: Amyloid fibrils activate
tyrosine kinase-dependent signaling and superoxide produc-
tion in microglia. J Neurosci 1997, 17:2284-2294.
51. Anderson KL, Ferreira A: alpha1 Integrin activation: a link
between beta-amyloid deposition and neuronal death in
aging hippocampal neurons. J Neurosci Res 2004, 75:688-697.
52. Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ: Local-
ization and cell association of C1q in Alzheimer's disease
brain. Exp Neurol 1996, 138:22-32.
53. Goldsmith SK, Wals P, Rozovsky I, Morgan TE, Finch CE: Kainic acid
and decorticating lesions stimulate the synthesis of C1q pro-
tein in adult rat brain. J Neurochem 1997, 68:2046-2052.
54. Fischer B, Schmoll H, Riederer P, Bauer J, Platt D, Popa-Wagner A:
Complement C1q and C3 mRNA expression in the frontal
cortex of Alzheimer's patients. J Mol Med 1995, 73:465-471.
55. Lee CK, Klopp RG, Weindruch R, Prolla TA: Gene expression pro-
file of aging and its retardation by caloric restriction. Science
1999, 285:1390-1393.
56. Fonseca MI, Kawas CH, Troncoso JC, Tenner AJ: Neuronal locali-
zation of C1q in preclinical Alzheimer's disease. Neurobiol Dis
2004, 15:40-46.
57. Hosokawa M, Klegeris A, Maguire J, McGeer PL: Expression of
complement messenger RNAs and proteins by human oli-
godendroglial cells. Glia 2003, 42:417-423.
58. Spielman L, Winger D, Ho L, Aisen PS, Shohami E, Pasinetti M: Induc-
tion of the complement component C1qB in brain of trans-
genic mice with neuronal overexpression of human
cyclooxygenase-2. Acta Neuropathol (Berl) 2002, 103:157-162.
59. Webster SD, Park M, Fonseca MI, Tenner AJ: Structural and func-
tional evidence for microglial expression of C1qRP, the C1q
receptor that enhances phagocytosis.  J Leukoc Biol 2000,
67:109-116.
60. Webster SD, Galvan MD, Ferran E, Garzon-Rodriguez W, Glabe CG,
Tenner AJ: Antibody-mediated phagocytosis of the amyloid β-
peptide in microglia is differentially modulated by C1q.  J
Immunol 2001, 166:7496-7503.
61. Tohgi H, Utsugisawa K, Nagane Y: Hypoxia-induced expression
of C1q, a subcomponent of the complement system, in cul-
tured rat PC12 cells. Neurosci Lett 2000, 291:151-154.
62. Takeuchi A, Miyaishi O, Kiuchi K, Isobe K: Macrophage colony-
stimulating factor is expressed in neuron and microglia after
focal brain injury. J Neurosci Res 2001, 65:38-44.
63. Wei R, Jonakait GM: Neurotrophins and the anti-inflammatory
agents interleukin-4 (IL-4), IL-10, IL-11 and transforming
growth factor-beta1 (TGF-beta1) down-regulate T cell cos-
timulatory molecules B7 and CD40 on cultured rat
microglia. J Neuroimmunol 1999, 95:8-18.
64. Linard C, Marquette C, Mathieu J, Pennequin A, Clarencon D, Mathe
D:  Acute induction of inflammatory cytokine expression
after gamma-irradiation in the rat: effect of an NF-kappaB
inhibitor. Int J Radiat Oncol Biol Phys 2004, 58:427-434.